Navigation Links
FDA Issues Complete Response Letter for Iclaprim
Date:1/19/2009

REINACH Switzerland, January 19 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) announces today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for intravenous iclaprim for the treatment of complicated skin and skin structure infections (cSSSI). The FDA indicated in its letter that they cannot approve the application for iclaprim in its current form and that additional clinical data are required to demonstrate efficacy in order to gain approval.

President and CEO Dr Jurgen Raths commented: "After the negative recommendation of the Advisory Committee of last November, the FDA opinion comes as no surprise. We now aim to develop a viable roadmap to approval in close consultation with the FDA. The drastic cost saving measures that we've recently implemented should buy us sufficient time to consider and develop strategic options for progressing iclaprim's development."

In its letter to Arpida, the FDA stated the Company's NDA did not demonstrate the efficacy of iclaprim for treatment of cSSSI within an acceptable non-inferiority margin. The FDA requires additional data to assess the benefits and risks of iclaprim for cSSSI.

To address this deficiency, the FDA requests an additional study or studies to demonstrate effectiveness of iclaprim. An additional study showing non-inferiority of iclaprim to an approved comparator may be sufficient to meet this requirement, depending on the study results.

Moreover, the FDA raised questions related to the drug product, which Arpida believes can be rapidly addressed. In addition, the resubmission should provide updated safety data and labelling information.

Arpida today also announces that the restructuring that was announced late last year, is progressing as planned. In addition, the Board of Directors has decided to decrease its membership
'/>"/>

SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
2. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on The Medical House PLC
4. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
5. OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc.
6. FDA Issues Draft Guidance on Priority Review Vouchers
7. Resverlogix Issues a Management Statement
8. SectorWatch.biz Issues MarketStats on Agri-Biotech Equities YGYB, GRO, SEED, MON, ADM, and BG
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
11. Arbitration Panel Issues Ruling in Distribution Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) ... Chief Financial Officer has resigned.  The Company has hired ... who retired in December 2014, as full time interim ... successor.     Andy Ashworth began his ... a smooth transition.  Andy was the Company,s CFO from ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... and supplier, announces the launch of their 2nd generation cell therapy POD® design. ... miniPOD CT, but it also represents a new POD® design. , “G-CON ...
(Date:7/29/2015)...  AmnioChor Inc., an early stage biotech startup based ... announce that the Musculoskeletal Transplant Foundation of ... their seed round of development of the proprietary AmnioCept™ ... AmnioChor,s technology allows cryopreservation of the amniotic ... living within those tissues. Amnion is a well-established source ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: INDV) ... naloxone nasal spray was accepted and received Priority Review ... the treatment of opioid overdose. This naloxone nasal spray ... formulated for optimal absorption into the nasal mucosa. 1 ... training so individuals may be better equipped to help ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... , WARSAW, Ind., Oct. 28 Zimmer Holdings, Inc. ... OMeGA Medical Grants Association LLC (OMeGA) has chosen its ... third party administrator for graduate medical education to which ... for the 2009-2010 academic year. , OMeGA received more ...
... PLYMOUTH MEETING, PA., Oct. 28 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation ... today announced,the appointment of Daniel P. Harrington to the ... Mr. Harrington brings more than thirty years of management ... traded,companies. Since 1995, he has been President and CEO ...
... Oct. 28 GenVec, Inc. (Nasdaq: GNVC ) announced ... ended September 30, 2009 on Thursday, November 5, 2009 after ... a.m. EST on Friday, November 6, 2009 to discuss the ... ) , To listen to the live conference ...
Cached Biology Technology:Zimmer Holdings Announces OMeGA Graduate Medical Education Grant Recipients 2Zimmer Holdings Announces OMeGA Graduate Medical Education Grant Recipients 3Zimmer Holdings Announces OMeGA Graduate Medical Education Grant Recipients 4BMP Sunstone Appoints Daniel Harrington to Board of Directors 2GenVec Announces Third Quarter 2009 Results Conference Call 2
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... than a holiday favorite, given their remarkable nutritional and health ... international journal Advances in Nutrition provides ... and not just a side dish. The review authors conclude ... the incidence of certain infections, improve heart health and temper ...
... Diseases affecting the kidneys represent a major and unsolved ... they are damaged by disease, highlighting the urgent need ... Now, a team of researchers led by scientists ... a novel platform to study kidney diseases, opening new ...
... Acta Obstetricia et Gynecologica Scandinavica , a journal of ... indicate that human error is the most common cause ... of clinical skills, and failure to obtain senior medical ... claims following birth asphyxia. In Norway there ...
Cached Biology News:Cranberries have health-promoting properties, new expert review reveals 2Cranberries have health-promoting properties, new expert review reveals 3Salk scientists for the first time generate 'mini-kidney' structures from human stem cells 2Salk scientists for the first time generate 'mini-kidney' structures from human stem cells 3Human error most common cause of birth asphyxia 2
... intended for use as a wash buffer for ... Fluid is useful for transportation of specimens (such ... studies. Samples may remain in Transport Fluid ... Michels Transport Fluid is not a fixative ...
... Systems provide rapid, precise localization of ... frozen or paraffin-embedded tissue, cytospins and ... facilitate double or triple labeleing experiments, ... with primary antibodies of different animal ...
... covers can be used with ... covers for stacking of covered ... for use with automated systems ... and non-ridged, are available for ...
SYBR Green Nucleic Acid Dye...
Biology Products: